Int J Med Sci 2013; 10(7):796-803. doi:10.7150/ijms.6048 This issue Cite

Review

Data Mining of the Public Version of the FDA Adverse Event Reporting System

Toshiyuki Sakaeda1✉, Akiko Tamon2, Kaori Kadoyama1, Yasushi Okuno3✉

1. Center for Integrative Education in Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan;
2. Kyoto Constella Technologies Co., Ltd., Kyoto 604-8156, Japan;
3. Department of Systems Biosciences for Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.

Citation:
Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int J Med Sci 2013; 10(7):796-803. doi:10.7150/ijms.6048. https://www.medsci.org/v10p0796.htm
Other styles

File import instruction

Abstract

The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses.

Keywords: adverse event, Adverse Event Reporting System, FAERS, database, data mining, signal, signal detection, proportional reporting ratio, reporting odds ratio, information component, empirical Bayes geometric mean, pharmacoepidemiology, pharmacovigilance.


Citation styles

APA
Sakaeda, T., Tamon, A., Kadoyama, K., Okuno, Y. (2013). Data Mining of the Public Version of the FDA Adverse Event Reporting System. International Journal of Medical Sciences, 10(7), 796-803. https://doi.org/10.7150/ijms.6048.

ACS
Sakaeda, T.; Tamon, A.; Kadoyama, K.; Okuno, Y. Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int. J. Med. Sci. 2013, 10 (7), 796-803. DOI: 10.7150/ijms.6048.

NLM
Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int J Med Sci 2013; 10(7):796-803. doi:10.7150/ijms.6048. https://www.medsci.org/v10p0796.htm

CSE
Sakaeda T, Tamon A, Kadoyama K, Okuno Y. 2013. Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int J Med Sci. 10(7):796-803.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image